What You Should Know:

你应该知道的：

–

–

Adaptive Biotechnologies Corporation

适应性生物技术公司

and

和

Flatiron Health

Flatiron Health

today announced the integration of Adaptive’s clonoSEQ® test for measurable residual disease (MRD) assessment in lymphoid malignancies into OncoEMR®, Flatiron’s cloud-based Electronic Medical Record (EMR) platform.

今天宣布将Adaptive的clonoSEQ®测试整合到Flatiron基于云的电子病历（EMR）平台OncoEMR®中，用于淋巴恶性肿瘤的可测量残留病灶（MRD）评估。

– The integration aims to simplify and accelerate access to MRD testing for over 4,500 clinicians across Flatiron’s network of 1,000 community-based cancer care locations in the U.S..

- 该集成旨在简化和加速美国Flatiron旗下1,000个社区癌症护理点网络中超过4,500名临床医生获取MRD检测的途径。

Enhancing Precision Oncology in Community Care

提升社区护理中的精准肿瘤学

MRD refers to the number of cancer cells that may remain in a patient’s body during and after treatment, which can eventually lead to disease recurrence. The status of MRD is a strong predictor of outcomes in blood cancer patients, and routine testing offers a personalized way to track an individual’s response to treatment and inform clinical decision-making for optimized care..

MRD是指在治疗期间和治疗后患者体内可能残留的癌细胞数量，这些细胞最终可能导致疾病复发。MRD状态是血液癌症患者结局的强有力预测指标，常规检测提供了一种个性化的方法来追踪个体对治疗的反应，并为优化护理提供信息以指导临床决策。

The integration, effective July 1, 2025, for all OncoEMR’s Molecular Profiling Integration (MPI) users , enables providers to order and review clonoSEQ MRD testing results directly within the EMR. This streamlined workflow is expected to provide more efficient testing and increase real-time insights into a patient’s disease status..

自2025年7月1日起，所有OncoEMR的分子谱型整合（MPI）用户将实现功能整合，使医疗提供者能够直接在电子病历（EMR）中订购和查看clonoSEQ MRD检测结果。这一简化的流程预计将提高检测效率，并增强对患者疾病状态的实时洞察。

Beyond the Flatiron network, clonoSEQ will continue to be accessible to providers through a rapidly expanding number of other EMR integrations and via Adaptive’s online diagnostic portal.

除了Flatiron网络之外，clonoSEQ还将继续通过越来越多的其他电子病历集成以及Adaptive的在线诊断门户向供应商提供。

We are thrilled to add clonoSEQ as the latest precision oncology test to be integrated within OncoEMR’s Molecular Profiling Integration (MPI) platform,” said Quincy Weatherspoon, VP & GM, Flatiron Point of Care Solutions at Flatiron Health. “MPI has demonstrated benefits for providers and for labs, as it facilitates rapid and accurate exchange of orders and results while also ensuring that every step in the testing workflow is interconnected and transparent.

我们非常高兴将clonoSEQ作为最新的精准肿瘤学测试整合到OncoEMR的分子分析集成（MPI）平台中，”Flatiron Health旗下Flatiron Point of Care Solutions副总裁兼总经理Quincy Weatherspoon表示。“MPI已经展示了对供应商和实验室的好处，因为它能够促进订单和结果的快速准确交换，同时还确保测试工作流程中的每一步都相互连接且透明。

Given clonoSEQ’s unique value proposition for blood cancer patients, we are proud to partner with Adaptive to advance the test’s role in community-based care.” .

鉴于clonoSEQ对血液癌患者独特的价值主张，我们很自豪能与Adaptive合作，推动该检测在社区医疗中的作用。”